Leader Loratadine-D 12 Hour combines selective H1-receptor antagonism with sympathomimetic nasal decongestant activity through 5mg loratadine and 120mg pseudoephedrine sulfate per extended-release tablet, delivering sustained 12-hour symptom management for allergic rhinitis and rhinosinusitis. The dual-mechanism formulation addresses both histamine-mediated allergic responses and adrenergic-dependent nasal mucosal edema, providing comprehensive relief from rhinorrhea, pruritus, lacrimation, and sinus pressure across indoor and outdoor allergen exposure scenarios. The extended-release matrix ensures steady medication delivery throughout the 12-hour interval, optimizing therapeutic efficacy while minimizing peak-related adverse effects. The non-sedating loratadine component maintains cognitive and psychomotor function, facilitating daytime use without impairment. The 30-tablet supply provides 15-day treatment duration with twice-daily dosing, supporting convenient allergy season management. This combination formulation represents an evidence-based therapeutic approach for individuals requiring simultaneous antihistamine and decongestant activity without requiring multiple separate medications or frequent dosing intervals.